Key result
Paroxetine coadministration significantly increased the AUC of R and S carvedilol enantiomers by approximately 2.5-fold and 1.9-fold, respectively, demonstrating a pharmacokinetic interaction.
Why the study?
Does paroxetine coadministration alter the stereospecific pharmacokinetics of carvedilol in healthy volunteers?
RCT (n=12)
randomized, 2-phase crossover
No
Does paroxetine coadministration alter the stereospecific pharmacokinetics of carvedilol in healthy volunteers?
Effect estimate: 2.5-fold (R) and 1.9-fold (S) increase
Paroxetine coadministration significantly increases the AUC of carvedilol enantiomers, demonstrating a pharmacokinetic drug-drug interaction.
Warrants carvedilol dose adjustment or monitoring with paroxetine; confirms CYP2D6-mediated stereospecific interaction in humans.
No abstract yet. The journal hasn't published one we can show.
No takes yet. Share an insight, caveat, or question.
Stout et al. (2010) conducted an RCT in healthy volunteers (n=12). Paroxetine vs. Without paroxetine was evaluated on Area under the concentration-time curve (AUC) for R and S carvedilol enantiomers (2.5-fold (R) and 1.9-fold (S) increase). Paroxetine coadministration significantly increased the AUC of R and S carvedilol enantiomers by approximately 2.5-fold and 1.9-fold, respectively, demonstrating a pharmacokinetic interaction.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: